EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Fosfomycin Trometamol in the Management of Urinary Tract Infection: A Focus on Antimicrobial Susceptibility and Resistance

Stefania Stefani, Carlo Tascini

Infection and Drug Resistance · 2026-07 · Volume 19 · 1-11

DOI: 10.2147/idr.s589847 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Infection and Drug Resistance, 2026-07. Verfasst von Stefania Stefani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urinary tract infections (UTIs) are common bacterial infections in women and vulnerable populations, with increasing incidence and prevalence worldwide. Although originally classified as uncomplicated or complicated, UTIs are now classified as localized (ie, cystitis) or systemic based on clinical signs and symptoms. Oral fosfomycin trometamol, a first-line antibiotic for localized UTIs, is active against several Gram-negative and Gram-positive bacteria, including extended-spectrum β-lactamase (ESBL)-producing Enterobacterales ; however, susceptibility testing and clinical breakpoints are recommended only for Escherichia coli . Susceptibility testing is also complicated by breakpoint differences of ≤ 64 mg/L (CLSI) versus 95% fosfomycin susceptibility was observed in Belgium, Spain, the United Kingdom, and Russia, versus 91.7% in Italy. Fosfomycin also appears to be an appropriate treatment option for localized UTIs in developing countries, with susceptibility rates of 78% to 100% among E. coli isolates and 85.3% to 100% among ESBL-producing E. coli isolates in India. Intracountry variation in fosfomycin susceptibility rates is observed, highlighting the importance of real-world data on local pathogen susceptibility patterns to optimize antibiotic prescribing and reduce antimicrobial resistance. Fosfomycin also shows promise in treating UTIs in vulnerable patient populations, including pediatric patients, pregnant women, men, and patients with catheter-associated UTIs. Keywords: antimicrobial resistance, antimicrobial susceptibility, fosfomycin trometamol, urinary tract infection

Schlagwörter

Stichwörter der Autor:innen

antimicrobial resistanceantimicrobial susceptibilityfosfomycin trometamolurinary tract infection

Autor:innen und Institutionen

  • Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
  • Department of Medicine, University of Udine, Udine, Italy.

Zitieren

APA

Stefani, S., & Tascini, C. (2026). Fosfomycin Trometamol in the Management of Urinary Tract Infection: A Focus on Antimicrobial Susceptibility and Resistance. Infection and Drug Resistance, Volume 19, 1-11. https://doi.org/10.2147/idr.s589847

Vancouver

Stefani S, Tascini C. Fosfomycin Trometamol in the Management of Urinary Tract Infection: A Focus on Antimicrobial Susceptibility and Resistance. Infection and Drug Resistance. 2026;Volume 19:1-11. doi:10.2147/idr.s589847

BibTeX
@article{Stefani2026,
  author = {Stefani, Stefania and Tascini, Carlo},
  title = {Fosfomycin Trometamol in the Management of Urinary Tract Infection: A Focus on Antimicrobial Susceptibility and Resistance},
  journal = {Infection and Drug Resistance},
  year = {2026},
  volume = {Volume 19},
  pages = {1--11},
  doi = {10.2147/idr.s589847}
}
Kostenlos starten →